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Abstract
Total pancreatectomy has occasionally been performed to treat patients with multiple lesions (such as intraductal
papillary mucinous neoplasm (IPMN)) or patients who have undergone repeated pancreatic resection. However,
deficiencies of the exocrine and endocrine functions worsen patients’ quality of life. Recently, there have been
several case reports citing middle segment-preserving pancreatectomy (MSPP) as a safe procedure and beneficial
with respect to preservation of the exocrine and endocrine functions. We herein report the case of a patient who
underwent MSPP for repeat pancreatectomy for IPMN and in whom a favorable outcome was achieved. The patient, a
70-year-old man, was diagnosed with branch duct-type IPMN (BD-IPMN) with worrisome features in the pancreatic
head and a single cyst in the pancreatic tail, during a preoperative examination of early gastric cancer.
Pancreatoduodenectomy was performed for BD-IPMN in the pancreatic head and gastric cancer. A histopathological
examination showed an intraductal papillary mucinous adenoma (IPMA) with mild-moderate atypia. During
the follow-up, the size of the cystic lesion in the pancreatic tail and the diameter of the main pancreatic duct were
gradually increasing. Therefore, at 2 years and 6 months after surgery, distal pancreatectomy with preservation of the
spleen (namely MSPP) was performed. The pancreatic resection margin was histologically negative. The length and
volume of the remnant pancreas were approximately 6 cm and 10 ml, respectively. A histopathological examination
showed an IPMA. The patient had no diarrhea or weight loss without digestive enzymes and maintained favorable
glucose tolerance without oral hypoglycemic agents or insulin. He has showed no evidence of new lesions in the
remnant pancreas at 3 years of follow-up after the last surgery.
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Background
Intraductal papillary mucinous neoplasm (IPMN) showed
synchronous or metachronous multifocal occurrence in ap-
proximately 20% of such patients [1]. The standard treat-
ment protocol is resection for the high risk of malignancy
and careful follow-up for the remaining low-risk lesions [2].
In patients with multiple lesions, total pancreatectomy (TP)
has occasionally been performed to achieve curative resec-
tion. Although the quality of life (QOL) has become accept-
able after TP due to improvements in the post-surgery
management [3, 4], TP can lead to diabetes mellitus (DM)
and related complications [5]. Recently, several case reports
have described middle segment-preserving pancreatectomy
(MSPP) as a safe procedure providing a favorable outcome
with respect to preservation of the exocrine and endocrine
functions [6]. We herein report a patient who underwent
MSPP for repeat pancreatectomy of IPMN in whom a
favorable outcome was achieved.
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Case presentation
A 70-year-old man was referred to our hospital for early
gastric cancer of the antrum. Abdominal computed tomog-
raphy (CT) for the preoperative staging showed cystic
lesions in the pancreatic head and tail. Therefore, a further
examination was performed. Magnetic resonance cholan-
giopancreatography (MRCP) and endoscopic retrograde
cholangiopancreatography (ERCP) showed a 33-mm-
diameter multilocular cystic lesion in the pancreatic head
and a 5-mm-diameter monolocular cyst in the pancreatic
tail (Fig. 1). The main pancreatic duct (MPD) was slightly
dilated at 4.5 mm. Endoscopic ultrasonography (EUS)
revealed a 7-mm-diameter intramural nodule in the cystic
lesion of the pancreatic head and no nodules in that of the
pancreatic tail. The lesion in the pancreatic head was diag-
nosed as a branch duct-type IPMN (BD-IPMN) with worri-
some features with a distinct nodule on EUS. It was
considered to be an indication for surgery. In contrast, the
lesion in the pancreatic tail was judged to be a low-risk
lesion with no indication for surgery. Therefore, pancreato-
duodenectomy (PD) was performed for the BD-IPMN in
the pancreatic head and gastric cancer. The left gastric
artery and vein were each ligated and divided. Reconstruc-
tion was carried out by the modified Child method.
A histopathological examination showed an intraductal
papillary mucinous adenoma (IPMA) with mild-moderate
atypia. Pancreatic epithelial cells in the stump showed no
atypia. After surgery, the patient was followed up every
6 months. During the follow-up, the size of the cystic le-
sion in the pancreatic tail and the diameter of the MPD
were gradually increasing. Two years and 6 months after
surgery, CT and MRCP revealed proximal extension of
the dilation of the MPD with a maximum diameter of
11 mm and a 16-mm-diameter cyst in the tail of the pan-
creas (Figs. 2 and 3). No intramural nodules in the MPD
or cystic lesion were detected. The patient was diagnosed
with IPMN with high-risk stigmata, and distal pancreatec-
tomy (DP) with preservation of the spleen, namely MSPP,
was performed. At laparotomy, the cystic lesion was
located at the pancreatic tail and the proximal MPD was
dilated. Intraoperative ultrasonography showed caliber
change of the MPD at the pancreatic body. Dissection be-
tween the future remnant pancreas and splenic artery/vein
was avoided in order not to injure the blood supply and
drainage. The pancreas was divided with a 2-cm margin
from that point (Fig. 4). The pancreatic resection margin
was histologically negative. The length and volume of the
remnant pancreas, as measured by postoperative CT, were
approximately 6 cm and 10 ml, respectively. A histopatho-
logical examination showed an IPMA with mild-moderate
atypia. No postoperative complications occurred, and the
patient was discharged on postoperative day 8 smoothly.
The patient had no diarrhea and weight loss without di-
gestive enzymes. In the 3 years of follow-up since the last
surgery, CT has never shown fatty liver or evidence of
new lesions in the remnant pancreas. He also maintained
favorable glucose tolerance without oral hypoglycemic
agents or insulin (Fig. 5).
Discussion
Siassi et al. [7] first reported the procedure of middle
segment-preserving pancreatectomy (MSPP) after distal
pancreatectomy in 1999. Since then, several case reports
have been published regarding the safety and effective-
ness of MSPP as an alternative to TP. Some authors
have recommended MSPP for patients with multicentric
noninvasive lesions, such as IPMNs, and pancreatic
Fig. 1 Endoscopic retrograde cholangiopancreatography. There were a
33-mm-diameter multilocular cystic lesion in the pancreatic head (arrow)
and a 5-mm-diameter monolocular cyst in the pancreatic tail (head of
arrow). The main pancreatic duct was slightly dilated at 4.5 mm
Fig. 2 Magnetic resonance cholangiopancreatography. The size of
the cyst in the pancreatic tail (arrow) and the diameter of the main
pancreatic duct (MPD) gradually increased (bracket). The examination
was performed 2 years and 6 months after the first surgery
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metastases, because lymphadenectomy was not neces-
sary [6, 8–10]. Recently, as a minimally invasive surgery,
laparoscopy-assisted MSPP was also reported [11].
Cheng et al. [6] reviewed 22 patients who underwent
MSPP and showed that the overall morbidity was 40.9%
(9/22), especially pancreatic fistula was 22.7% (5/22) with
no mortality. Thus, MSPP was a safe and feasible proced-
ure, and it has come to be widely performed for selected
patients.
Postoperative exocrine and endocrine insufficiency is a
major concern in pancreatectomy. Okano et al. [12] ana-
lyzed 227 patients who underwent PD or DP to deter-
mine the relationship between pancreatic volume and
the postoperative pancreatic function. A volume of the
remnant pancreas <24.1 ml was the only independent
predictive factor for postoperative exocrine insufficiency;
therefore, they recommended pancreatic enzyme therapy
for these patients. Cheng et al. [6] reported that exocrine
insufficiency after MSPP developed in 6 of 22 (27.3%)
with a median follow-up of 18 months. Similarly, several
other reports have described the relationship between
the remnant volume of the pancreas and the postopera-
tive endocrine function [13, 14]. Kang et al. [15] ana-
lyzed 101 patients who underwent DP and reported that
a resected pancreatic volume >25% was a risk factor for
endocrine impairment. Cheng et al. [6] also reported
that endocrine insufficiency after MSPP developed in 7
of 22 patients (31.8%). Therefore, with respect to pre-
serving the pancreas, these findings indicated that MSPP
allows patients to avoid exocrine and endocrine insuffi-
ciency after surgery. In the present case, the volume of
the remnant pancreas was very small (10 ml), which is
18.9% of the total pancreas; thus, the risk of postopera-
tive exocrine and endocrine insufficiency was expected
to be very high. Fortunately, our patient has maintained
exocrine and endocrine functions without any kind of
medication for more than 3 years after the second
Fig. 3 Computed tomography. A caliber change in the MPD at the
pancreatic body was detected (arrow head). The cyst was located in
the pancreatic tail (arrow)
Fig. 4 Operative findings. The pancreas was divided by a 2-cm margin
from the point of caliber change of the MPD (arrow). The line indicated
the resection line of the pancreas (a). The splenic artery and vein were
preserved, and the remnant pancreas measured approximately 6 cm in
length (b). SpA splenic artery, SpV splenic vein
Fig. 5 The changes in glucose tolerance after surgery
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surgery. While the reason for this favorable outcome re-
mains unclear, we speculate several reasons. First, at the
initial surgery, the pancreatic function in the pancreatic
body and tail was preserved because the pancreas head
tumor was IPMN and not pancreatic cancer, and ob-
structive pancreatitis had not developed. Second, the
resected pancreas in the last surgery was atrophic, and
little of the functioning pancreas volume was lost. Third,
we preserved the blood supply and drainage as much as
possible. These conditions might have contributed to the
good maintenance of the exocrine and endocrine func-
tions of the remnant pancreas.
In addition, several reports have indicated that splenec-
tomy is one of the risk factors for postoperative endocrine
sufficiency. Hutchins et al. [16] analyzed 90 patients who
underwent DP for chronic pancreatitis and reported that
the incidence of DM after DP was lower in patients with-
out splenectomy than in those with splenectomy (43 vs
72%). Tang et al. [17] retrospectively reviewed 82 patients
who underwent DP with splenectomy and 78 patients
who underwent DP without splenectomy for benign and
borderline malignant tumors. They showed that fewer
patients with splenectomy developed postoperative DM in
comparison to patients who were treated without splenec-
tomy (2.5 vs 12.2%). Thus, in cases in which an oncologi-
cally curative resection can be maintained (such as in the
present case), the spleen should be preserved to provide a
favorable endocrine function after surgery.
The preservation of the splenic artery was very im-
portant. First, although there have been no reports of
pancreatic ischemia after MSPP, the blood supply to the
remnant pancreas should be evaluated before surgery
[8, 18]. The pancreatic body is mainly supplied by the
splenic artery. In fact, in the present case, several small
vessels to the pancreas, which originated from the
splenic artery, were observed by preoperative CT. Sec-
ond, the splenic artery has also been reported to be
responsible for the main blood supply to the remnant
stomach after distal gastrectomy [19]. In our case, the
preservation of these vessels enabled the prevention of
total gastrectomy.
Conclusions
By performing DP with preservation of the spleen after
PD and distal gastrectomy, namely MSPP for IPDA, we
have preserved the postoperative exocrine and endocrine
functions of the pancreas for more than 3 years since
the last surgery. MSPP for selected patients therefore
helps to ensure a high QOL after surgery.
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